Cargando…
Beyond new chemical entities: Advancing drug development based on functional versatility of antibodies
Antibody-type agents (i.e., antibodies and derivatives thereof) may be produced as clinically valuable antidotes, which conceivably could be developed in tandem with prospective new pharmaceutical products so as to render the risks of clinical trials more acceptable from a regulatory standpoint. Yet...
Autor principal: | Caoili, Salvador Eugenio C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185958/ https://www.ncbi.nlm.nih.gov/pubmed/24632567 http://dx.doi.org/10.4161/hv.28192 |
Ejemplares similares
-
Antidotes, antibody-mediated immunity and the future of pharmaceutical product development
por: Caoili, Salvador Eugenio C.
Publicado: (2013) -
Benchmarking B-Cell Epitope Prediction with Quantitative Dose-Response Data on Antipeptide Antibodies: Towards Novel Pharmaceutical Product Development
por: Caoili, Salvador Eugenio C.
Publicado: (2014) -
On the Meaning of Affinity Limits in B-Cell Epitope Prediction for Antipeptide Antibody-Mediated Immunity
por: Caoili, Salvador Eugenio C.
Publicado: (2012) -
Antibodies, synthetic peptides and related constructs for planetary health based on green chemistry in the Anthropocene
por: Caoili, Salvador Eugenio
Publicado: (2018) -
Comprehending B-Cell Epitope Prediction to Develop Vaccines and Immunodiagnostics
por: Caoili, Salvador Eugenio C.
Publicado: (2022)